Niclosamide had an IC50 of 0.34 μM for inhibition of Wnt/β-catenin transcription using a TOPFlash reporter assay (Mook et al., 2015), which matches closely the IC50 of 0.13 μM we measured for inhibition of the TMEM16A, a molecular target also implicated in cancer. Here, ANO1 is linked to cancer.